Wise Health System

WiseRegional.com

At Wise Health System, we’re committed to leading the growth and development of health care services in our area and providing quality, specialized care for you and your family. In 2006, Wise Regional opened the doors to our new 176,000-square- foot hospital that features 99 private patient rooms in a spacious and welcoming environment. We apply a progressive philosophy in the delivery of health care and continue to expand services as well as purchase advanced equipment to provide our community with the latest in diagnostics, treatment and support. Our service market has expanded tremendously over the last 5 years and we currently provide services at 48 different service locations in 8 counties.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BGN TECHNOLOGIES ANNOUNCES RESEARCH COLLABORATION AGREEMENT WITH ECOIBÉRIA IN THE FIELD OF PLASTIC RECYCLING BY BACTERIA

BGN Technologies | November 05, 2020

news image

BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev (BGU), announced today that it had signed a research collaboration agreement with ECOIBÉRIA in the field of plastic recycling by bacteria, based on research from the team of Prof. Ariel Kushmaro and Prof. Alex Sivan, both from the Laboratory of Environmental Biotechnology and Avram and Stella Goldstein-Goren Department of Biotechnology Engineering at BGU. Polyethylene terephthalate (PET) is the most ab...

Read More

MEDTECH

COSMOSID LAUNCHES ACCURATE AND EASY FUNCTIONAL MICROBIOME ANALYSIS WITH NEW SOFTWARE PLATFORM, COSMOSID-HUB: MICROBIOME

CosmosID | September 27, 2021

news image

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming...

Read More

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

news image

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More

CELL AND GENE THERAPY

IMARA ANNOUNCES PRIMARY ENDPOINT CHANGE IN THE ARDENT PHASE 2B CLINICAL TRIAL OF TOVINONTRINE (IMR-687) IN SICKLE CELL DISEASE

Imara | November 22, 2021

news image

Imara Inc. a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA). Imara requested f...

Read More
news image

BGN TECHNOLOGIES ANNOUNCES RESEARCH COLLABORATION AGREEMENT WITH ECOIBÉRIA IN THE FIELD OF PLASTIC RECYCLING BY BACTERIA

BGN Technologies | November 05, 2020

BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev (BGU), announced today that it had signed a research collaboration agreement with ECOIBÉRIA in the field of plastic recycling by bacteria, based on research from the team of Prof. Ariel Kushmaro and Prof. Alex Sivan, both from the Laboratory of Environmental Biotechnology and Avram and Stella Goldstein-Goren Department of Biotechnology Engineering at BGU. Polyethylene terephthalate (PET) is the most ab...

Read More
news image

MEDTECH

COSMOSID LAUNCHES ACCURATE AND EASY FUNCTIONAL MICROBIOME ANALYSIS WITH NEW SOFTWARE PLATFORM, COSMOSID-HUB: MICROBIOME

CosmosID | September 27, 2021

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming...

Read More
news image

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More
news image

CELL AND GENE THERAPY

IMARA ANNOUNCES PRIMARY ENDPOINT CHANGE IN THE ARDENT PHASE 2B CLINICAL TRIAL OF TOVINONTRINE (IMR-687) IN SICKLE CELL DISEASE

Imara | November 22, 2021

Imara Inc. a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA). Imara requested f...

Read More